Novo Nordisk is facing a cluster of lawsuits filed in courts across the country, each raising questions about how the company prices, markets, and discloses risks for its GLP-1 drugs, including Ozempic. The claims range from allegations that patients were misled about safety to accusations that pricing tactics were used to keep cheaper competitors off the market. For anyone taking or considering a GLP-1 medication, these cases could shape what information reaches patients, what drugs are available, and at what price, in the months and years ahead.
One lawsuit, Thompson v. Novo Nordisk, Inc., alleges that the company misled patients about the weight loss benefits of Ozempic while withholding information about safety risks. The case is still ongoing, and the specific risks in question have not been detailed in public filings so far. Claims like this matter because they go directly to what patients are told before they start a medication, not just how it is priced or marketed. If the allegations hold up, the outcome could affect how Novo Nordisk communicates risk information to patients going forward.
A second case, Landon v. Novo Nordisk, Inc., takes a different angle and accuses the company of using pricing and marketing tactics designed to keep cheaper GLP-1 alternatives out of reach. This kind of claim focuses less on what patients were told and more on what choices they actually had at the pharmacy counter. If a company can structure pricing in a way that discourages competitors from entering the market, patients may end up paying more for longer than they otherwise would. The case is ongoing, and its outcome could influence how GLP-1 pricing is scrutinized in future disputes.
A separate matter, Shroff v. Eli Lilly and Company, does not involve Novo Nordisk directly but could still shape the broader GLP-1 market. This case is a patent dispute over technology behind Eli Lilly's GLP-1 drugs, and it remains pending. Patent disputes like this determine which companies are legally allowed to manufacture competing versions of a drug, so the resolution could affect how many GLP-1 options are available and when. For patients watching for lower cost alternatives, this case is one to keep an eye on, even though it will take time to resolve.
Another lawsuit, Harris v. Novo Nordisk, Inc., is pending against the company over its GLP-1 drugs, though the specific claims have not yet become public. Cases like this one often follow a familiar pattern in pharmaceutical litigation, where the details emerge gradually as the case moves through discovery. Based on how similar lawsuits have unfolded, this case could eventually lead to changes in drug labeling or to a settlement between the parties. Patients should not expect immediate changes, but the case is worth tracking as more information becomes available.
A final case in this group, Slaton v. Novo Nordisk A/S, challenges the company's pricing and marketing of GLP-1 drugs, and it follows a pattern seen in other pharmaceutical litigation. The substance of the claims has not been made public yet, but similar cases in the past have led to changes in drug labeling or resulted in settlements between the companies and plaintiffs. This pattern gives some indication of how the case might resolve, though nothing is guaranteed at this stage. Readers who want to understand how pricing disputes typically play out may find it useful to watch how this case compares to the others filed against Novo Nordisk.
None of these cases have reached a resolution yet, and the specific claims in several of them are still not public. For patients currently taking a GLP-1 medication, the most useful step is to talk with a prescribing doctor about any questions raised by these lawsuits, rather than making changes based on litigation alone. It may also help to watch for updates on label changes or settlements as these cases move forward, since that is often when the practical effects become clear. Staying informed about both the safety claims and the pricing disputes can help patients make sense of a market that is still working through some significant legal challenges.
Key details
A lawsuit claims Novo Nordisk misled patients about Ozempic and hid safety risks.
Novo Nordisk faces claims it used pricing tactics to block cheaper GLP-1 rivals.
A patent dispute over Eli Lilly's GLP-1 technology could affect future competition.
A separate lawsuit against Novo Nordisk could lead to label changes or settlements.
Another Novo Nordisk lawsuit over pricing mirrors cases that lead to settlements.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-08-26